Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. Read more about Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
Metastatic insulinoma-outcomes in the current era. Read more about Metastatic insulinoma-outcomes in the current era.
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Read more about Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.
Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Read more about Proceedings of the 1st biannual bridging the gaps in lung cancer conference.
Immune-related encephalitis after immune checkpoint inhibitor therapy. Read more about Immune-related encephalitis after immune checkpoint inhibitor therapy.
Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer. Read more about Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Read more about Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial. Read more about Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series. Read more about Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series.
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Read more about HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
